Standard Digital Weekend Print + Standard Digital Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%. Global news & analysis Expert opinion FT App on Android & iOS FT Edit app FirstFT: the day’s biggest stories 20+ curated newsletters Follow topics & set alerts…
Solskin The biotechnology sector has been a hotbed of innovation and progress, with companies making groundbreaking strides in areas like gene therapy, cancer treatments, and regenerative medicine. This progress, coupled with promising financial returns, has made the sector an attractive investment option. Unfortunately, the momentum just hasn’t been there. Most biotech stocks peaked in 2021…
pepifoto There’s the man, and then there’s the index. There’s the index, and then there’s the ETF. A lot of people are familiar with media personality Joe Terranova. He’s got an index and a fund that seeks to track that index which is rules-based. The methodology is worth taking a look at independent of Mr….
SweetBunFactory You’d think that with all this AI hype, semi stocks broadly would be doing well. This of course until you dig deeper and realize how much of this narrative is being driven by just one stock (Nvidia, my fav!). Semiconductor stocks outside of Nvidia (NVDA) really haven’t done all that much since 2021, but…
tadamichi The trouncing of smaller caps by mega-cap stocks has been one of the hallmark market themes of this year, with the S&P 500® Top 50 outpacing the S&P SmallCap 600® by 30% YTD.1 As a result of its inherent small-cap bias, the S&P 500 Equal Weight Index ((EWI)) has suffered accordingly, underperforming the S&P…